UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in irritable bowel syndrome and how to avoid them

Robin Spiller

Summary

AI Generated

This material addresses common mistakes in the diagnosis and management of irritable bowel syndrome, a heterogeneous condition affecting 11% of the global population with varied bowel habit presentations.

  • IBS affects approximately 11% of the worldwide population, making it one of the most frequent gastroenterological diagnoses.
  • All IBS patients experience recurrent abdominal pain, but bowel habits vary: around one-third have predominantly diarrhoea (IBS-D), one-fifth have predominantly constipation (IBS-C), and half have a mixed pattern (IBS-M).
  • The author states that IBS has multiple causes and requires an individualized approach to management and treatment.
  • The material is intended to review frequent mistakes in IBS diagnosis and management, based on published data and clinical experience.
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160: 99-114 e113.
2.
Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407.e1395.
3.
Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917.
4.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-820.
5.
Hasler WL and Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005.
6.
van Lanen AS, de Bree A and Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021; 60: 3505-3522.
7.
Staudacher HM, Rossi M, Kaminski T, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241.
8.
Hill LS, Reid F, Morgan JF, et al. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43: 344-351.
9.
Mari A, Hosadurg D, Martin L, et al. Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 2019; 31: 178-182.
10.
Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328 e321-323.
11.
Suarez FL, Savaiano DA and Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
12.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268 e261.
13.
Khasawneh M, Shaikh FA, Ng CE, et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol Motil 2024; 36: e14756.
14.
Houghton LA and Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-511.
15.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-1010.
16.
Barba E, Burri E, Quiroga S, et al. Visible abdominal distension in functional gut disorders: Objective evaluation. Neurogastroenterol Motil 2023; 35: e14466.
17.
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015; 9: 332-339.
18.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
19.
Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-1270 e1261.
20.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614-620.
21.
van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
22.
Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71.
23.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496.
24.
Drossman D and Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2: 22-30.
25.
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374.
26.
Kennedy TM and Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-1663.
27.
Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. Surg Endosc 2011; 25: 3379-3384.
28.
Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31: 953-960.
29.
Longstreth GF and Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673.
30.
Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23: 552.

Abstract

Around 11% of the worldwide population experience irritable bowel syndrome (IBS), making it one of the most frequent gastroenterological diagnoses.1 The symptoms of IBS include abdominal pain associated with unpredictable bowel habits and variable changes in the form and frequency of stool.2 While all patients with IBS suffer from recurrent bouts of abdominal pain, their bowel habits are varied: around one-third suffer predominantly with diarrhoea (IBS-D), one-fifth experience predominantly constipation (IBS-C) and half have an erratic mixed pattern of both diarrhoea and constipation (IBS-M).3 This very heterogeneous condition undoubtedly has multiple causes and an individualized approach to management and treatment is required. Here I discuss the mistakes most frequently made when diagnosing and managing IBS. The mistakes and discussion that follow are based, where possible, on published data and failing that on many years of my own clinical experience.

Topics

Neurogastroenterology & Motility Primary Care

Citation

Spiller R. Mistakes in irritable bowel syndrome and how to avoid them. UEG Education 2016: 16; 31–33.

Published

2024

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Standards and Guidelines
Consensus
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Guideline

ABSTRACT

Introduction

Chronic nausea and vomiting are symptoms of a wide range of gastrointestinal and non-gastrointestinal conditions. Diagnosis can be challenging and requires a systematic and well-structured approach. If the initial investigation for structural, toxic and metabolic disorders is negative, digestive motility and gut-brain interaction disorders should be assessed. United European Gastroenterology (UEG) and the European Society for Neurogastroenterology and Motility (ESNM) identified the need for an updated, evidence-based clinical guideline for the management of chronic nausea and vomiting.

Methods

A multidisciplinary team of experts in the field, including European specialists and national societies, participated in the development of the guideline. Relevant questions were addressed through a literature review and statements were developed and voted on according to a Delphi process.

Results

Ninety-eight statements were identified and voted following the Delphi process. Overall agreement was high, although the grade of scientific evidence was low in many areas. Disagreement was more evident for some pharmacological treatment options. A diagnostic algorithm was developed, focussing on the differentiating features between gastrointestinal motility and gut-brain interaction disorders with predominant nausea and vomiting.

Conclusion

These guidelines provide an evidence-based framework for the evaluation and treatment of patients with chronic nausea and vomiting.

Publisher

European Society of Neurogastroenterology and Motility logo
European Society of Neurogastroenterology and Motility

Guideline

Consensus

Topics

Neurogastroenterology & Motility Paediatrics Primary Care Stomach & H. Pylori

Citation

United European Gastroenterol J.

Published

2025

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord, Roos E. Pouw

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160: 99-114 e113.
2.
Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407.e1395.
3.
Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917.
4.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-820.
5.
Hasler WL and Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005.
6.
van Lanen AS, de Bree A and Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021; 60: 3505-3522.
7.
Staudacher HM, Rossi M, Kaminski T, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241.
8.
Hill LS, Reid F, Morgan JF, et al. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43: 344-351.
9.
Mari A, Hosadurg D, Martin L, et al. Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 2019; 31: 178-182.
10.
Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328 e321-323.
11.
Suarez FL, Savaiano DA and Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
12.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268 e261.
13.
Khasawneh M, Shaikh FA, Ng CE, et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol Motil 2024; 36: e14756.
14.
Houghton LA and Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-511.
15.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-1010.
16.
Barba E, Burri E, Quiroga S, et al. Visible abdominal distension in functional gut disorders: Objective evaluation. Neurogastroenterol Motil 2023; 35: e14466.
17.
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015; 9: 332-339.
18.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
19.
Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-1270 e1261.
20.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614-620.
21.
van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
22.
Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71.
23.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496.
24.
Drossman D and Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2: 22-30.
25.
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374.
26.
Kennedy TM and Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-1663.
27.
Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. Surg Endosc 2011; 25: 3379-3384.
28.
Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31: 953-960.
29.
Longstreth GF and Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673.
30.
Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23: 552.

Abstract

Proton pump inhibitors (PPIs), first introduced with omeprazole in 1988, revolutionized the treatment of gastric acid-related conditions like gastro-oesophageal reflux disease, gastroduodenal ulcers, and Helicobacter pylori infections. Despite their effectiveness, PPIs are often prescribed for conditions without a proven link to gastric acid, such as dyspepsia and upper abdominal discomfort. Long-term use of PPIs has raised safety concerns, including risks of vitamin and mineral malabsorption, pneumonia, gastrointestinal infections, and dementia. This Mistakes In article addresses nine common mistakes in PPI use and aims to clarify misconceptions about their use.

Topics

Digestive Oncology Oesophagus

Citation

Pouw R.E. and Bredenoord A.J. Mistakes in the use of PPIs and how to avoid them. UEG Education 2017; 17: 15–17.

Published

2024

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

MASLD with Sven Francque - Part 2

Sven Francque, Pradeep Mundre

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Topics

Hepatobiliary

Published

2026

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo, Javier Molina-Infante

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160: 99-114 e113.
2.
Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407.e1395.
3.
Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917.
4.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-820.
5.
Hasler WL and Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005.
6.
van Lanen AS, de Bree A and Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021; 60: 3505-3522.
7.
Staudacher HM, Rossi M, Kaminski T, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241.
8.
Hill LS, Reid F, Morgan JF, et al. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43: 344-351.
9.
Mari A, Hosadurg D, Martin L, et al. Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 2019; 31: 178-182.
10.
Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328 e321-323.
11.
Suarez FL, Savaiano DA and Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
12.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268 e261.
13.
Khasawneh M, Shaikh FA, Ng CE, et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol Motil 2024; 36: e14756.
14.
Houghton LA and Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-511.
15.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-1010.
16.
Barba E, Burri E, Quiroga S, et al. Visible abdominal distension in functional gut disorders: Objective evaluation. Neurogastroenterol Motil 2023; 35: e14466.
17.
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015; 9: 332-339.
18.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
19.
Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-1270 e1261.
20.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614-620.
21.
van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
22.
Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71.
23.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496.
24.
Drossman D and Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2: 22-30.
25.
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374.
26.
Kennedy TM and Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-1663.
27.
Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. Surg Endosc 2011; 25: 3379-3384.
28.
Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31: 953-960.
29.
Longstreth GF and Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673.
30.
Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23: 552.

Abstract

Eosinophilic oesophagitis (EoE) is a chronic immune-mediated inflammatory condition that is confined to the oesophagus. Clinically, EoE is characterized by symptoms of oesophageal dysfunction; histologically, by eosinophil-predominant inflammation.1,2 At present, EoE is the second-most frequent cause of chronic oesophagitis (gastro-oesophageal reflux disease [GORD] is the primary cause) and the foremost cause of dysphagia and food impaction in young adults and children.

Topics

Oesophagus

Citation

Molina-Infante J and Lucendo AJ. Mistakes in eosinophilic oesophagitis and how to avoid them. UEG Education 2017: 17; 6–9.

Published

2024

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in jejunal feeding and how to avoid them

Ashley Bond, Simon Lal

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160: 99-114 e113.
2.
Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407.e1395.
3.
Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917.
4.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-820.
5.
Hasler WL and Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005.
6.
van Lanen AS, de Bree A and Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021; 60: 3505-3522.
7.
Staudacher HM, Rossi M, Kaminski T, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241.
8.
Hill LS, Reid F, Morgan JF, et al. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43: 344-351.
9.
Mari A, Hosadurg D, Martin L, et al. Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 2019; 31: 178-182.
10.
Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328 e321-323.
11.
Suarez FL, Savaiano DA and Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
12.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268 e261.
13.
Khasawneh M, Shaikh FA, Ng CE, et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol Motil 2024; 36: e14756.
14.
Houghton LA and Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-511.
15.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-1010.
16.
Barba E, Burri E, Quiroga S, et al. Visible abdominal distension in functional gut disorders: Objective evaluation. Neurogastroenterol Motil 2023; 35: e14466.
17.
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015; 9: 332-339.
18.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
19.
Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-1270 e1261.
20.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614-620.
21.
van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
22.
Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71.
23.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496.
24.
Drossman D and Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2: 22-30.
25.
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374.
26.
Kennedy TM and Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-1663.
27.
Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. Surg Endosc 2011; 25: 3379-3384.
28.
Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31: 953-960.
29.
Longstreth GF and Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673.
30.
Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23: 552.

Abstract

Topics

Small Intestine & Nutrition

Citation

Bond A and Lal S. Mistakes in jejunal feeding and how to avoid them. UEG Education 2020; 20: 17–19. 

Published

2020

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in Familial Mediterranean Fever and how to avoid them

Manik Gemilyan, Gagik Hakobyan

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology 2021; 160: 99-114 e113.
2.
Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology 2016; 150: 1393-1407.e1395.
3.
Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917.
4.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-820.
5.
Hasler WL and Schoenfeld P. Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 997-1005.
6.
van Lanen AS, de Bree A and Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr 2021; 60: 3505-3522.
7.
Staudacher HM, Rossi M, Kaminski T, et al. Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome. Neurogastroenterol Motil 2022; 34: e14241.
8.
Hill LS, Reid F, Morgan JF, et al. SCOFF, the development of an eating disorder screening questionnaire. Int J Eat Disord 2010; 43: 344-351.
9.
Mari A, Hosadurg D, Martin L, et al. Adherence with a low-FODMAP diet in irritable bowel syndrome: are eating disorders the missing link? Eur J Gastroenterol Hepatol 2019; 31: 178-182.
10.
Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013; 145: 320-328 e321-323.
11.
Suarez FL, Savaiano DA and Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
12.
Yang J, Deng Y, Chu H, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013; 11: 262-268 e261.
13.
Khasawneh M, Shaikh FA, Ng CE, et al. Utility of irritable bowel syndrome subtypes and most troublesome symptom in predicting disease impact and burden. Neurogastroenterol Motil 2024; 36: e14756.
14.
Houghton LA and Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-511.
15.
Houghton LA, Lea R, Agrawal A, et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology 2006; 131: 1003-1010.
16.
Barba E, Burri E, Quiroga S, et al. Visible abdominal distension in functional gut disorders: Objective evaluation. Neurogastroenterol Motil 2023; 35: e14466.
17.
Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver 2015; 9: 332-339.
18.
Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015; 42: 3-11.
19.
Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-1270 e1261.
20.
Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4: 614-620.
21.
van Rheenen PF, Van de Vijver E and Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369.
22.
Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 2004; 89: 69-71.
23.
Tuteja AK, Biskupiak J, Stoddard GJ, et al. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil 2010; 22: 424-430, e496.
24.
Drossman D and Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol Suppl 2014; 2: 22-30.
25.
Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol 2017; 112: 365-374.
26.
Kennedy TM and Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658-1663.
27.
Kirk G, Kennedy R, McKie L, et al. Preoperative symptoms of irritable bowel syndrome predict poor outcome after laparoscopic cholecystectomy. Surg Endosc 2011; 25: 3379-3384.
28.
Breuer NF, Jaekel S, Dommes P, et al. Fecal bile acid excretion pattern in cholecystectomized patients. Dig Dis Sci 1986; 31: 953-960.
29.
Longstreth GF and Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-1673.
30.
Alderson SL, Wright-Hughes A, Ford AC, et al. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care. Trials 2022; 23: 552.

Abstract

Familial Mediterranean fever (FMF), also called periodic disease, Armenian disease, etc., is a prototypical autoinflammatory disorder where the underlying mechanism is the dysfunction of innate immunity, resulting in unprovoked episodes of inflammation.1 Although considered rare worldwide, it is prevalent in people of Mediterranean origin; however, one can expect to encounter patients in all parts of the modern world. FMF is a monogenic disease with autosomal recessive inheritance.2 Unlike other monogenic disorders, the diagnosis remains largely clinical, and it is important to understand the limitations of genetic testing. Another distinguishing feature is the well-established effectiveness of lifelong monotherapy with colchicine in preventing attacks and complications.3

Topics

Primary Care

Published

2025

More Like This:

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

European Guideline on Chronic Nausea and Vomiting—A UEG and ESNM Consensus for Clinical Management

Carolina Malagelada Carolina Malagelada

Mistakes in the use of PPIs and how to avoid them

Mistakes in the use of PPIs and how to avoid them

Albert J. Bredenoord Albert J. Bredenoord, Roos E. Pouw

MASLD with Sven Francque - Part 2

MASLD with Sven Francque - Part 2

Pradeep Mundre Pradeep Mundre, Sven Francque

Mistakes in eosinophilic oesophagitis and how to avoid them

Mistakes in eosinophilic oesophagitis and how to avoid them

Alfredo J. Lucendo Alfredo J. Lucendo, Javier Molina-Infante

Mistakes in jejunal feeding and how to avoid them

Mistakes in jejunal feeding and how to avoid them

Ashley Bond Ashley Bond, Simon Lal

Mistakes in Familial Mediterranean Fever and how to avoid them

Mistakes in Familial Mediterranean Fever and how to avoid them

Gagik Hakobyan Gagik Hakobyan, Manik Gemilyan

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.